Patents by Inventor Bireshwar Dasgupta

Bireshwar Dasgupta has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • PYRROLOTRIAZINE KINASE INHIBITORS
    Publication number: 20160243125
    Abstract: The present disclosure is generally directed to compounds which can inhibit AAK1 (adaptor associated kinase 1), compositions comprising such compounds, and methods for inhibiting AAK1.
    Type: Application
    Filed: October 8, 2014
    Publication date: August 25, 2016
    Inventors: Carolyn Diane Dzierba, Bireshwar Dasgupta, John E. Macor, Joanne J. Bronson, Ramkumar Rajamani, George N. Karageorge
  • NOVEL SUBSTITUTED PYRAZOLO-PIPERAZINES AS CASEIN KINASE 1 D/E INHIBITORS
    Publication number: 20160122358
    Abstract: The invention provides compounds of Formula (I): and pharmaceutically acceptable salts thereof. The compounds of Formula (I) inhibit protein kinase activity thereby making them useful as anticancer agents.
    Type: Application
    Filed: January 13, 2016
    Publication date: May 5, 2016
    Inventors: Upender Velaparthi, Chetan Padmakar Darne, Peiying Liu, Mark D. Wittman, Bradley C. Pearce, Erika M. V. Araujo, Bireshwar Dasgupta, Jalathi Surendran Nair, Sakthi Kumaran Janakiraman, Chandrasekhar Reddy Rachamreddy, Mallikarjuna Rao Mettu, Arul Mozhi Subbiah Karuppiah, Subba Reddy Bandreddy, Nagalakshmi Pulicharla, Rajesh Onkardas Bora, Shilpa Maheshwarappa Holehatti, Selvakumar Kumaravel, Dibakar Mullick, Ramesh Kumar Sistla
  • Substituted pyrazolo-piperazines as casein kinase 1 ?/? inhibitors
    Patent number: 9273058
    Abstract: The invention provides compounds of Formula (I): and pharmaceutically acceptable salts thereof. The compounds of Formula (I) inhibit protein kinase activity thereby making them useful as anticancer agents.
    Type: Grant
    Filed: November 14, 2014
    Date of Patent: March 1, 2016
    Assignee: Bristol-Myers Squibb Company
    Inventors: Upender Velaparthi, Chetan Padmakar Darne, Peiying Liu, Mark D. Wittman, Bradley C. Pearce, Erika M. V. Araujo, Bireshwar Dasgupta, Jalathi Surendran Nair, Sakthi Kumaran Janakiraman, Chandrasekhar Reddy Rachamreddy, Mettu Mallikarjuna Rao, Arul Mozhi Selvan Subbiah Karuppiah, Bandreddy Subba Reddy, Pulicharla Nagalakshmi, Rajesh Onkardas Bora, Shilpa Holehatti Maheshwarappa, Selvakumar Kumaravel, Dibakar Mullick, Ramesh Sistla
  • NOVEL SUBSTITUTED PYRAZOLO-PIPERAZINES AS CASEIN KINASE 1 D/E INHIBITORS
    Publication number: 20150133428
    Abstract: The invention provides compounds of Formula (I): and pharmaceutically acceptable salts thereof. The compounds of Formula (I) inhibit protein kinase activity thereby making them useful as anticancer agents.
    Type: Application
    Filed: November 14, 2014
    Publication date: May 14, 2015
    Inventors: Upender Velaparthi, Chetan Padmakar Darne, Peiying Liu, Mark D. Wittman, Bradley C. Pearce, Erika M. V. Araujo, Bireshwar Dasgupta, Jalathi Surendran Nair, Sakthi Kumaran Janakiraman, Chandrasekhar Reddy Rachamreddy, Mettu Mallikarjuna Rao, Arul Mozhi Selvan Subbiah Karuppiah, Bandreddy Subba Reddy, Pulicharla Nagalakshmi, Rajesh Onkardas Bora, Shilpa Holehatti Maheshwarappa, Selvakumar Kumaravel, Dibakar Mullick, Ramesh Sistla
  • Imidazolyl derivatives as corticotropin releasing factor inhibitors
    Patent number: 7238699
    Abstract: The present invention relates to novel heterocyclic antagonists of Formula (I) and pharmaceutical compositions comprising said antagonists of the corticotropin releasing factor receptor (“CRF receptor”) useful for the treatment of depression, anxiety, affective disorders, feeding disorders, post-traumatic stress disorder, headache, drug addiction, inflammatory disorders, drug or alcohol withdrawal symptoms and other conditions the treatment of which can be effected by the antagonism of the CRF-1 receptor.
    Type: Grant
    Filed: February 4, 2004
    Date of Patent: July 3, 2007
    Assignee: Bristol-Myers Squibb Company
    Inventors: Vivekananda M. Vrudhula, Bireshwar Dasgupta, Gene M. Dubowchik, John E. Macor
  • Imidazolyl derivatives as corticotropin releasing factor inhibitors
    Patent number: 7211669
    Abstract: The present invention relates to novel heterocyclic antagonists of Formula (I) and pharmaceutical compositions comprising said antagonists of the corticotropin releasing factor receptor (“CRF receptor”) useful for the treatment of depression, anxiety, affective disorders, feeding disorders, post-traumatic stress disorder, headache, drug addiction, inflammatory disorders, drug or alcohol withdrawal symptoms and other conditions the treatment of which can be effected by the antagonism of the CRF-1 receptor.
    Type: Grant
    Filed: January 29, 2004
    Date of Patent: May 1, 2007
    Assignee: Bristol-Myers Squibb Company
    Inventors: Vivekananda M. Vrudhula, Dmitry Zuev, Bireshwar Dasgupta
  • Atropisomers of 3-substituted-4-arylquinolin-2-one derivatives
    Patent number: 6939968
    Abstract: Atropisomers of 3-substituted-4-arylquinolin-2-one derivatives having the general formula wherein R, R1, R2, R3, R4 and R5, are as defined herein, or a non-toxic pharmaceutically acceptable salt, solvate or prodrug thereof. The atropisomers can modulate the large conductance calcium-activated K+ channels and are useful in the treatment of disorders which are responsive to the opening of the potassium channels. In addition, the atropisomers can be stable, i.e., do not interconvert, for periods of up to one month, or more.
    Type: Grant
    Filed: December 17, 2003
    Date of Patent: September 6, 2005
    Assignee: Bristol-Myers Squibb Company
    Inventors: Vivekananda M. Vrudhula, Valentin Kala Gribkoff, Bireshwar Dasgupta, Christopher G. Boissard
  • Imidazolyl derivatives as corticotropin releasing factor inhibitors
    Patent number: 6888004
    Abstract: The present invention relates to novel heterocyclic antagonists of Formula (I) and pharmaceutical compositions comprising said antagonists of the corticotropin releasing factor receptor (“CRF receptor”) useful for the treatment of depression, anxiety, affective disorders, feeding disorders, post-traumatic stress disorder, headache, drug addiction, inflammatory disorders, drug or alcohol withdrawal symptoms and other conditions the treatment of which can be effected by the antagonism of the CRF-1 receptor.
    Type: Grant
    Filed: January 11, 2002
    Date of Patent: May 3, 2005
    Assignee: Bristol-Myers Squibb Company
    Inventors: Gene M. Dubowchik, Vivekananda M. Vrudhula, Dmitry Zuev, Bireshwar Dasgupta, John E. Macor
  • Imidazolyl derivatives as corticotropin releasing factor inhibitors
    Publication number: 20040254382
    Abstract: The present invention relates to novel heterocyclic antagonists of Formula (I) and pharmaceutical compositions comprising said antagonists of the corticotropin releasing factor receptor (“CRF receptor”) 1
    Type: Application
    Filed: January 29, 2004
    Publication date: December 16, 2004
    Inventors: Vivekananda M. Vrudhula, Dmitry Zuev, Bireshwar Dasgupta
  • Imidazolyl derivatives as corticotropin releasing factor inhibitors
    Publication number: 20040225001
    Abstract: The present invention relates to novel heterocyclic antagonists of Formula (I) and pharmaceutical compositions comprising said antagonists of the corticotropin releasing factor receptor (“CRF receptor”) 1
    Type: Application
    Filed: February 4, 2004
    Publication date: November 11, 2004
    Inventors: Vivekananda M. Vrudhula, Bireshwar Dasgupta, Gene M. Dubowchik, John E. Macor
  • Atropisomers of 3-substituted-4-arylquinolin-2-one derivatives
    Publication number: 20040147749
    Abstract: Atropisomers of 3-substituted-4-arylquinolin-2-one derivatives having the general formula 1
    Type: Application
    Filed: December 17, 2003
    Publication date: July 29, 2004
    Inventors: Vivekananda M. Vrudhula, Valentin Kala Gribkoff, Bireshwar Dasgupta, Christopher G. Boissard
  • Imidazolyl derivatives as corticotropin releasing factor inhibitors
    Publication number: 20020183375
    Abstract: The present invention relates to novel heterocyclic antagonists of Formula (I) and pharmaceutical compositions comprising said antagonists of the corticotropin releasing factor receptor (“CRF receptor”) 1
    Type: Application
    Filed: January 11, 2002
    Publication date: December 5, 2002
    Inventors: Gene M. Dubowchik, Xiaojun Han, Vivekananda M. Vrudhula, Dmitry Zuev, Bireshwar Dasgupta, Jodi A. Michne
  • Neurotrophic difluoroamide agents
    Patent number: 6239146
    Abstract: The present invention relates to the design, synthesis, and the peptidyl-prolyl isomerase (PPIase or rotamase) inhibitory activity of novel &agr;,&agr;-difluoroacetamido compounds that are neurotrophic agents (i.e. compounds capable of stimulating growth or proliferation of nervous tissue) and that bind to immunophilins such as FKBP12 and inhibit their rotamase activity. This invention also relates to pharmaceutical compositions comprising these compounds.
    Type: Grant
    Filed: June 9, 2000
    Date of Patent: May 29, 2001
    Assignee: Bristol-Myers Squibb Company
    Inventors: Vivekananda M. Vrudhula, Gene M. Dubowchik, Bireshwar Dasgupta, Dolatrai M. Vyas
  • Neurotrophic difluoroamide agents
    Patent number: 6096762
    Abstract: The present invention relates to the design, synthesis, and the peptidyl-prolyl isomerase (PPIase or rotamase) inhibitory activity of novel .alpha.,.alpha.-difluoroacetamido compounds that are neurotrophic agents (i.e. compounds capable of stimulating growth or proliferation of nervous tissue) and that bind to immunophilins such as FKBP12 and inhibit their rotamase activity. This invention also relates to pharmaceutical compositions comprising these compounds.
    Type: Grant
    Filed: May 21, 1999
    Date of Patent: August 1, 2000
    Assignee: Bristol-Myers Squibb Company
    Inventors: Vivekananda M. Vrudhula, Gene M. Dubowchik, Bireshwar Dasgupta, Dolatrai M. Vyas